TRiCares Successfully Closes Series C Financing, Raising €51m to Fund Further Development and Clinical Trials of Minimally Invasive Treatment for Tricuspid Regurgitation
Scenic Biotech and the Barth Syndrome Foundation Announce Partnership to Explore Genetic Modifiers to a Find Tailored Treatment for the Complex Rare Disease
Cardior Raises €64 M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease
29.07.2021
Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$48 Million) in this Round
06.07.2021
TRiCares Announces Successful First in Human Implantations of Minimally Invasive Topaz Tricuspid Heart Valve Replacement System
28.06.2021
Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer
15.06.2021
Alentis Therapeutics Raises USD 67 Million in Series B Financing
11.05.2021
Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board
20.04.2021
Tubulis appoints Günter Fingerle - Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs
04.10.2022
TRiCares Raises €47m in a First Closing of its Series C Financing to Fund Further Development of Minimally Invasive Treatment for Tricuspid Regurgitation
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
25.03.2021
Inotrem bolsters leadership team with the appointment of Sven Zimmermann as new CEO
21.12.2023
Inotrem receives approval to expand nangibotide clinical trial in critically ill COVID-19 patients and receive additional public funding of €45 million
Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma
Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA
21.12.2023
Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease
Cardior Announces First Patient Dosed in Phase 2 Study Evaluating Efficacy and Safety of Non-coding RNA- Based Lead Candidate CDR132L in Heart Failure Patients Post- Myocardial Infarction